Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress

Author's Avatar
Oct 22, 2021

-- Study uses Invitae Personalized Cancer Monitoring (PCM™) liquid biopsy to accurately profile tumors and enhance cancer circulating tumor DNA-based minimal residual disease (MRD) lead times; highlights promise for personalized cancer care --

PR Newswire